{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:04:31Z","timestamp":1765814671322,"version":"3.48.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"50","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the second batch of major (key) science and technology plan projects in Jinhua","award":["2022-3-101"],"award-info":[{"award-number":["2022-3-101"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,12]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Mantle-cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma. Bruton tyrosine kinase inhibitors (BTKi) significantly improve the prognosis of MCL, but their long-term use may induce immunosuppression-related complications, including secondary malignancies. First-generation BTKi such as Ibrutinib have been reported to be associated with the development of skin cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 77-year-old male patient with MCL treated with the next-generation highly selective BTKi Orelabrutinib (150mg\/ day) developed multiple different types of skin tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Skin pathological examination confirmed basal cell carcinoma of the nose, squamous cell carcinoma, actinic keratosis and seborrheic keratosis of the chest skin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Orelabrutinib was suspended and switched to chemotherapy. The nasal and chest skin tumors were resected, the nasal wound was repaired with adjacent flap, and the chest wound was repaired with skin grafting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The wound recovered well after the operation, but the patient died of multiple organ failure due to pulmonary infection 5 months later.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>Orelabrutinib may be associated with multiple skin tumors, and the mechanism may be through complex immune dysregulation. It is recommended that patients receiving long-term BTKi therapy undergo regular dermatological examinations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000046417","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:00:51Z","timestamp":1765814451000},"page":"e46417","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Multiple skin tumors in a patient treated with orelabrutinib for mantle-cell lymphoma: Case report"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7994-8568","authenticated-orcid":false,"given":"Xuefeng","family":"Fu","sequence":"first","affiliation":[{"name":"Department of Dermatology, Jinhua Municipal Central Hospital Medical Group, Jinhua, Zhejiang Province, China"},{"name":"Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Jinhua Municipal Central Hospital Medical Group, Jinhua, Zhejiang Province, China"},{"name":"Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Jinhua Municipal Central Hospital Medical Group, Jinhua, Zhejiang Province, China"},{"name":"Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Jinhua Municipal Central Hospital Medical Group, Jinhua, Zhejiang Province, China"},{"name":"Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefeng","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Jinhua Municipal Central Hospital Medical Group, Jinhua, Zhejiang Province, China"},{"name":"Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20251215","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3324\/haematol.2009.013359","article-title":"Mantle cell lymphoma.","volume":"94","author":"Pileri","year":"2009","journal-title":"Haematologica"},{"key":"R2-20251215","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/17425255.2024.2334322","article-title":"Metabolic and toxicological considerations of Bruton\u2019s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia\/small lymphocytic lymphoma.","volume":"20","author":"Wolska-Washer","year":"2024","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R3-20251215","doi-asserted-by":"crossref","first-page":"e01120","DOI":"10.1016\/j.idcr.2021.e01120","article-title":"Cutaneous mucormycosis in a chronic lymphocytic leukemia patient on ibrutinib.","volume":"24","author":"Sittig","year":"2021","journal-title":"IDCases"},{"key":"R4-20251215","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13613-023-01219-5","article-title":"Severe infections requiring intensive care unit admission in patients receiving ibrutinib for hematological malignancies: a groupe de recherche respiratoire en r\u00e9animation onco-h\u00e9matologique (GRRR-OH) study.","volume":"13","author":"Baucher","year":"2023","journal-title":"Ann Intensive Care"},{"key":"R5-20251215","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12985-023-02140-w","article-title":"Hepatitis B virus reactivation in seronegative occult hepatitis B patient receiving ibrutinib therapy.","volume":"20","author":"Lam","year":"2023","journal-title":"Virol J"},{"key":"R6-20251215","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1038\/s41375-020-0987-6","article-title":"Second cancer incidence in CLL patients receiving BTK inhibitors.","volume":"34","author":"Bond","year":"2020","journal-title":"Leukemia"},{"key":"R7-20251215","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3390\/cancers16111960","article-title":"Skin malignancies due to anti-cancer therapies.","volume":"16","author":"Starace","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R8-20251215","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s40164-023-00448-5","article-title":"Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies.","volume":"12","author":"Song","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"R9-20251215","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1001\/jamadermatol.2020.2571","article-title":"Association of age, sex, race, and geographic region with variation of the ratio of basal cell to cutaneous squamous cell carcinomas in the United States.","volume":"156","author":"Lukowiak","year":"2020","journal-title":"JAMA Dermatol"},{"key":"R10-20251215","first-page":"265","article-title":"Seborrheic keratosis.","volume":"21","author":"Barthelmann","year":"2023","journal-title":"J Dtsch Dermatol Ges"},{"key":"R11-20251215","first-page":"675","article-title":"Diagnosis and therapy of actinic keratosis.","volume":"22","author":"Thamm","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"key":"R12-20251215","doi-asserted-by":"crossref","first-page":"113403","DOI":"10.1016\/j.ejca.2023.113403","article-title":"Secondary malignancies among mantle cell lymphoma patients.","volume":"195","author":"Abalo","year":"2023","journal-title":"Eur J Cancer"},{"key":"R13-20251215","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.hoc.2020.05.002","article-title":"Molecular pathogenesis of mantle cell lymphoma.","volume":"34","author":"Navarro","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"key":"R14-20251215","first-page":"439","article-title":"A review of the bruton tyrosine kinase inhibitors in B-cell malignancies.","volume":"12","author":"Moore","year":"2021","journal-title":"J Adv Pract Oncol"},{"key":"R15-20251215","doi-asserted-by":"crossref","first-page":"166584","DOI":"10.1016\/j.jmb.2020.06.023","article-title":"Discovery and function of B cell IgD low (BDL) B cells in immune tolerance.","volume":"433","author":"Khalil","year":"2021","journal-title":"J Mol Biol"},{"key":"R16-20251215","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jdermsci.2016.09.007","article-title":"JAK inhibitor JTE-052 regulates contact hypersensitivity by downmodulating T cell activation and differentiation.","volume":"84","author":"Amano","year":"2016","journal-title":"J Dermatol Sci"},{"key":"R17-20251215","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.7314\/APJCP.2015.16.6.2303","article-title":"Roles of white blood cells and subtypes as inflammatory markers in skin cancer.","volume":"16","author":"Baykan","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"R18-20251215","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00401-022-02411-w","article-title":"BTK inhibition limits B-cell-T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy.","volume":"143","author":"Li","year":"2022","journal-title":"Acta Neuropathol"},{"key":"R19-20251215","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.4049\/jimmunol.1900321","article-title":"Dissection of the effects of JAK and BTK inhibitors on the functionality of healthy and malignant lymphocytes.","volume":"203","author":"Hofland","year":"2019","journal-title":"J Immunol"},{"key":"R20-20251215","doi-asserted-by":"crossref","first-page":"1533444","DOI":"10.3389\/fimmu.2025.1533444","article-title":"Advances in primary large B-cell lymphoma of immune-privileged sites.","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"R21-20251215","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.3324\/haematol.2019.220590","article-title":"Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma.","volume":"105","author":"Flinsenberg","year":"2020","journal-title":"Haematologica"},{"key":"R22-20251215","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/jid.2011.9","article-title":"Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated.","volume":"131","author":"Pettersen","year":"2011","journal-title":"J Invest Dermatol"},{"key":"R23-20251215","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ejca.2021.10.034","article-title":"Ibrutinib-related skin cancer: a pharmacovigilance study from the Food and Drug Administration Adverse Event Reporting System.","volume":"160","author":"Sun","year":"2022","journal-title":"Eur J Cancer"},{"key":"R24-20251215","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.critrevonc.2019.02.001","article-title":"Management of adverse effects\/toxicity of ibrutinib.","volume":"136","author":"Paydas","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"R25-20251215","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1182\/bloodadvances.2022009168","article-title":"Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1\/2, open-label, multicenter, single-arm study.","volume":"7","author":"Deng","year":"2023","journal-title":"Blood Adv"},{"key":"R26-20251215","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11523-021-00857-8","article-title":"Bruton tyrosine kinase inhibitors in B-cell malignancies: their use and differential features.","volume":"17","author":"Shirley","year":"2022","journal-title":"Target Oncol"},{"key":"R27-20251215","doi-asserted-by":"crossref","first-page":"adv00140","DOI":"10.2340\/00015555-3495","article-title":"Update in the management of basal cell carcinoma.","volume":"100","author":"Basset-Seguin","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"R28-20251215","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.asjsur.2022.04.079","article-title":"High-risk cutaneous squamous cell carcinoma (CSCC): challenges and emerging therapies.","volume":"46","author":"Halim","year":"2023","journal-title":"Asian J Surg"},{"key":"R29-20251215","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40257-020-00535-x","article-title":"Dermatological toxicities of bruton\u2019s tyrosine kinase inhibitors.","volume":"21","author":"Sibaud","year":"2020","journal-title":"Am J Clin Dermatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046417","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:00:55Z","timestamp":1765814455000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":29,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046417","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"2025-05-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}